SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
PharmaCielo Ltd. (PCLOF) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 23/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PCLOF
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio2.54
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.01
Book Value / Share$0.00
Revenue / Share$0.01
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.22 |
$0.00 |
$-11.26M |
- |
| 2017 |
$-0.04 |
$0.00 |
$-15.98K |
- |
| 2018 |
$-1.18 |
$0.00 |
$-31.63M |
- |
| 2019 |
$-0.36 |
$786.9K |
$-34.67M |
-4405.6% |
| 2020 |
$-0.39 |
$2.65M |
$-43.76M |
-1648.7% |
| 2021 |
$-0.18 |
$1.94M |
$-26.63M |
-1369.1% |
| 2022 |
$-0.11 |
$5.31M |
$-14.52M |
-273.5% |
| 2023 |
$-0.10 |
$1.54M |
$-16.3M |
-1057.1% |
| 2024 |
$-0.05 |
$3.48M |
$-9.14M |
-262.7% |
| 2025 |
$-0.01 |
$2.6M |
$-3.98M |
-153% |
